Clinical trial Recruiting at 1 site Interventional Ages 18 and up

Improve implant site by adding a soft-tissue graft substitute over a bone graft

Official title: Phenotype Modification Via Guided Bone Regeneration and Acellular Dermal Matrix Simultaneous to Delayed Implant Placement: A Double Arm Randomized Controlled Clinical Trial.

Run by University of Michigan · NCT07082244 · Data updated 2026-11-12

We will test whether placing a soft-tissue graft substitute (acellular dermal matrix) over a bone graft at single implant sites helps improve the bone and gum health, appearance, and stability for adults with horizontal ridge deficiency.

Quick facts

Study typeInterventional
Ages18 Years and up
SexAll
Enrollment40 (estimated)
SponsorUniversity of Michigan
Academic / other
Drugs / interventionschemotherapy, radiation
Locations1 site (Ann Arbor, Michigan)
StatusRecruiting
StartedJune 1, 2025
Main results expectedJanuary 1, 2027
Study endsSeptember 1, 2027
Registry record updatedJuly 30, 2026
Trial IDNCT07082244 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Adults (≥18 years) with one healed edentulous region in the anterior maxilla or premolar/canine mandible (≥3 months post-extraction), a thin periodontal phenotype with Seibert Class I horizontal ridge deficiency, good oral hygiene, and ASA I–II health status.

Probably not a fit

Patients with uncontrolled or untreated periodontal disease, current smokers (including cannabis and e-cigarettes), or those taking medications that impair bone healing are unlikely to benefit and may be excluded.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

Adults needing a single implant at a previously healed edentulous site (>3 months post-extraction) will receive implant placement with guided bone regeneration (GBR) using a collagen membrane and bone graft. Half of participants will also receive an acellular dermal matrix (ADM) soft-tissue graft substitute placed over the grafted site. Outcomes will include measures of bone and soft-tissue health, esthetic appearance, and stability of the peri-implant tissues over follow-up visits. The protocol excludes current smokers, patients with uncontrolled periodontal disease, and those on medications known to affect bone healing.

Why it matters

Potential benefit: If successful, adding an ADM over GBR could improve soft-tissue thickness, esthetics, and long-term stability around single dental implants.

How similar studies have gone: Previous work combining GBR with soft-tissue substitutes like ADM has shown some positive effects on soft-tissue thickness and esthetics, but results are mixed and high-quality controlled data remain limited.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

* Age ≥ 18 years.
* Subjects with a physical status of systemically healthy or suffering from mild to moderate, but well-controlled disease; American Society of Anesthesiology (ASA) I or II.
* Subjects must have one edentulous region, with at least 3 months of healing post-extraction, in the esthetic zone of the maxilla or the premolar and canine region of the mandible. This region includes the maxillary premolars, canines, and incisors.
* Subjects must have a full mouth plaque and bleeding score of less than or equal to 20%, measured at four sites per tooth.
* The patients should have a thin periodontal phenotype; bucco-lingual ridge thickness greater than 6mm.
* Seibert class I deficiency (Seibert, 1983)
* Patients willing to sign the informed consent.

Exclusion Criteria:

* Presence of uncontrolled and/or untreated periodontal disease.
* Patients currently smoking cigarettes, cannabis, and electronic cigarettes.
* Subjects taking medications known to impact bone metabolism or have the capacity to affect wound healing. These drugs include bisphosphonates, corticosteroids, parathyroid hormone, RANKL inhibitors, past exposure to head and neck radiation, chemotherapy within the last 12 months, among others.
* Subjects with systemic diseases that impact bone metabolism and wound healing. Namely, osteoporosis, osteopenia, hyperparathyroidism, Paget's disease.
* Allergy to the graft materials.
* Pregnant subjects or individuals who self-report as attempting to become pregnant.
* Patient's unwilling to sign the informed consent.

Where it's running

  • University of Michigan
    Ann Arbor, Michigan, United States
    Recruiting

Study contacts

  • Principal investigator: Muhammad Saleh, BDS, MSD — University of Michigan
  • Study coordinator: David Dunbar, DDS
  • Email: dgdunbar@umich.edu
  • Phone: 734-763-3346

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.